To Michael Celano, Chairman of the Board, please go ahead.
Good morning. Welcome to the OraSure Technologies 2018 Annual Meeting of Shareholders. My name is Mike Celano, and as stated, I'm Chairman of the Board of Directors. I also serve as Chairman of the company's Audit Committee and serve on the Compensation Committee. As my principal occupation, I am the Chief Operating Officer of Recro Pharma, a specialty pharmaceutical company. I'll be acting as Chairman of this meeting. With me today are Steve Tang, OraSure's President and CEO, and Ron Spair, Chief Operating Officer and Chief Financial Officer for the company. Steve and Ron are also members of the Board. Jack Jerrett, OraSure's General Counsel, is also here and will act as Secretary of the meeting. We are pleased to again be conducting this meeting in a completely virtual format. There are several items of business to be considered as explained in our proxy statement.
Following these items, there will be a Q&A session during which stockholders attending the meeting may ask questions. Questions may be submitted by following the instructions on the website page for this meeting and in the meeting notice sent to the stockholders. You may submit your questions now and at any time during the meeting. Only questions that are germane to the matters being discussed at today's meeting will be considered. An archived audio copy of the meeting will be available on the webpage for the meeting approximately 24 hours after our meeting concludes, and will remain available for a period of seven business days thereafter. The Inspector of Election for this meeting is Ms. Anna Hagberg of Broadridge Financial Solutions. Ms. Hagberg has taken an oath, which will be included with the minutes of this meeting.
Broadridge has also provided us with an affidavit certifying that notices of this meeting were sent on March 29th, 2018, to all stockholders of record as of March 15th record date. Notice of this meeting has therefore been given in accordance with the company's bylaws and applicable law. As required by law, a complete list of the stockholders entitled to vote at this meeting is available for inspection by any stockholder for any purpose germane to this meeting. This list may be accessed on the website for the meeting. According to both the company's records and certificate of the inspector, there are 61,494,102 shares of the company's common stock in total to vote at this meeting. The inspector has determined that persons holding a majority of the outstanding shares of stock are attending this meeting by proxy.
Accordingly, I declare that a quorum is present, the 2018 Annual Meeting of Stockholders is now called to order. Before proceeding further, I would like to introduce the additional members of the company's board of directors. Each of these directors are attending this meeting. From the board, we have Mara Aspinall, President and CEO of Health Catalysts Group, an investment advisory firm serving healthcare and technology companies. Mara serves on the Audit and Compensation Committees. Eamonn Hobbs, President of Hobbs Medical Ventures, a healthcare consulting company. Eamonn also serves on the Audit and Compensation Committees. Ronny Lancaster, Senior VP for Federal Government Relations of Assurant, Inc., a global provider of risk management solutions. Ronny is chairman of our Compensation Committee and serves on the Nominating and Corporate Governance Committee. Charles Patrick, Principal of Patrick Consulting.
Chuck is chairman of the Nominating and Corporate Governance Committee and serves on the Audit Committee. Lilach Schory-Man , Executive Vice President, Head of Corporate Business Development and Strategy of Alexion Pharmaceuticals. Alexion is a global biopharmaceutical company. Lilach serves on the Audit Committee and the Nominating and Corporate Governance Committee. Before I go further, I would note that Roberto Cuca is also attending the meeting. As you may recall, we had recently announced that Roberto has been appointed as the company's new Chief Financial Officer, effective as of June 8, 2018. I'd like to officially welcome Roberto to the company. Roberto will be replacing Ron Spair, who will be retiring from the company and resigning his position of Chief Financial Officer and Chief Operating Officer, and as a member of the board.
On behalf of my fellow directors and all of the company's employees, I would like to thank Ron for his many years of service and contributions to the company. We wish Ron and his family nothing but the best for the future. Finally, Joe Kalinowski from KPMG is also attending the meeting electronically. KPMG is the company's independent registered public accounting firm. Joe is available to respond to questions raised during the Q&A session if necessary. Before proceeding with the formal agenda, I would like to make a few brief remarks about OraSure's performance during 2017. This was another very strong year for the company, with record financial performance on both the top and the bottom lines. Our consolidated net revenues were $167.1 million, a 30% increase over 2016. Consolidated net product revenues increased 51% over 2016.
Our consolidated net income was $30.9 million, or $0.51 per share, which represents an $11.2 million improvement over the prior year. 2017 was OraSure's third consecutive full year of profitability. Our strong financial performance contributed to a total stockholder return of almost 115% for 2017. Once again, our molecular collection systems business was a primary driver of our performance, with 2017 revenues of $75.1 million, an increase of 133% over the prior year. Our OraQuick HCV test was also an important contributor with international sales growth of 156% in 2017 compared to 2016. Finally, international HIV sales grew 115% compared to 2016. This primarily reflects increased sales of our OraQuick HIV self-test in Africa. As we begin 2018, we are pleased with the state of our business and are excited about the opportunities ahead of us.
We are very confident in our business strategy and believe we are on the right track to deliver long-term value to our stockholders. With that, I will now move into the formal part of the stockholder meetings. The order of business will be set forth in a proxy statement. A copy of the agenda is available on the website for this meeting. The business transaction today will be limited to three items. The polls are open for voting by following the directions on the website and in the meeting notice sent to our stockholders. After all business items have been discussed, I will close the polls and no further voting will be permitted. As indicated in the agenda, the first item of business is the election of two class 3 directors. The board nominees are Charles Patrick and Michael Celano.
The class 3 directors elected today will hold office until the company's annual meeting in the year 2021. Each nominee is presently a director of the company and has consented to serve if elected. The names of the director nominees have been placed into nomination. Additional information about each nominee can be found in our proxy statement. No other nominations were made in accordance with the procedures established by the company's bylaws. Accordingly, the nominations have been closed. The company's board of directors is recommending that the stockholders vote for the director nominees. The second item of business is the ratification of the appointment of KPMG LLP as the company's independent registered public accounting firm for 2018. KPMG has served this capacity for the past several years.
The appointment of KPMG has been approved by the audit committee and the board in recommending that stockholders vote for ratification of KPMG's appointment. The third item of business is the approval by a non-binding advisory vote of the compensation of the company's named executive officers, as disclosed in our proxy statement. Federal law requires that we provide stockholders with the opportunity to vote on compensation paid to executives. This is commonly referred to as a say on pay vote. Setting appropriate levels of executive compensation is an important issue and one we take very seriously. We believe our top executive compensation for 2017 is competitive and fully aligned with our pay for performance philosophy. Accordingly, the board is recommending that stockholders vote for approval of the resolution on executive compensation as set forth in the proxy statements.
The polls will be closed momentarily, if you've not done so yet, please cast your vote at this time. The stockholders desiring to vote have now had an opportunity to vote their shares either prior to today or during the meeting. Accordingly, I declare the polls are closed. I ask the inspector tally the votes and prepare a certificate of results. There being no further business to conduct, the formal portion of the meeting is now adjourned. In the time remaining, we will answer questions if there are any. There does not appear to be any questions, I will now conclude the Q&A session. Before ending the webcast, I would like to provide a preliminary report on the voting as prepared by the inspector.
Taking into account the number of shares represented at the meeting, a tabulation of all the proxies and ballots indicates that on a preliminary basis, the nominees for the board have been reelected. The appointment of KPMG has been ratified. The compensation of the company's named executive officers as described in the proxy statement, has been approved. A written certificate of the final vote totals for each of these items will be prepared by the inspector and filed with the minutes for the meeting. These results will also be disclosed by the company in an upcoming SEC filing. That is all we have for today. On behalf of the company and the board, I would like to thank all of our shareholders for your continued support and for your participation in this year's meeting.
This concludes the OraSure Technologies, Inc. Annual Meeting of Shareholders. Thank you for attending today's presentation. You may now disconnect.